Last reviewed · How we verify
Valpin (octatropine methylbromide)
At a glance
| Generic name | octatropine methylbromide |
|---|---|
| Sponsor | Endo |
| Drug class | octatropine methylbromide |
| Target | Muscarinic acetylcholine receptor M1 |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1962 |
Approved indications
- Gastric ulcer
- Peptic ulcer
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valpin CI brief — competitive landscape report
- Valpin updates RSS · CI watch RSS
- Endo portfolio CI